NCT02607774View on ClinicalTrials.gov

Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 17, 2015

Primary Completion Date

December 20, 2016

Study Completion Date

December 20, 2016

Conditions
Moderate to Severe Plaque Psoriasis
Interventions
DRUG

Midazolam

midazolam administered to all patients Days -7, 1 and 35.

DRUG

AIN457

secukinumab administered at Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24

Trial Locations (8)

23507

Novartis Investigative Site, Norfolk

35205

Novartis Investigative Site, Birmingham

71913

Novartis Investigative Site, Hot Springs

75230

Novartis Investigative Site, Dallas

77004

Novartis Investigative Site, Webster

85032

Novartis Investigative Site, Phoenix

07410

Novartis Investigative Site, Fair Lawn

07044

Novartis Investigative Site, Verona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY